Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
HER3 and mutant EGFR meet MET | Nature Medicine
1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC - ScienceDirect
BioModels
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors - The Lancet Oncology
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib - Journal of Thoracic Oncology
Figure 1 | Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. - Abstract - Europe PMC
Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody* - Journal of Biological Chemistry
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
PLOS ONE: Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer | PGPM
Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis - The American Journal of Pathology
Met signaling pathway and EGF receptor tyrosine kinase inhibitor... | Download Scientific Diagram
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer | Biomarker Research | Full Text
Crosstalk between c-Met and EGFR. a, b The tyrosine kinase receptors... | Download Scientific Diagram
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer | Clinical Cancer Research
![PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fb34e0b378ab283ee885fb912c61cc28ae8a288b/3-Figure1-1.png "PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar")
PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar
c-MET Proto-oncogene | Targeting Overexpression
